|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2021-07-27 |
A 12-week, double-blind, international, multicenter, dose-response study of the safety and efficacy of Beraprost Sodium Modified Release (BPS-MR) in patients with pulmonary arterial hypertension (PAH)
A Multi-center, open-label, multiple dose, dose finding study exploring the safety and tolerability of Beraprost Sodium Modified Release in PAH patients
100 项与 Lung Rx Ltd. 相关的临床结果
0 项与 Lung Rx Ltd. 相关的专利(医药)
100 项与 Lung Rx Ltd. 相关的药物交易
100 项与 Lung Rx Ltd. 相关的转化医学